Pfizer says booster in children 5-11 raises antibodies against omicron

A booster dose of the Pfizer-BioNTech Covid-19 vaccine raised antibody levels in children ages 5 to 11, the company said Thursday.

The additional shot, given six months after the two-dose primary series, led to a sixfold increase in antibodies against the original strain of the coronavirus.

The clinical trial of the booster shot included 140 children ages 5 through 11. In a smaller sub-analysis of 30 kids in the trial, Pfizer said the additional dose led to a thirtysixfold increase in antibodies against the omicron variant of the virus.

Pfizer announced...